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Abstract
Background Chemotherapy-induced nausea and vomiting
(CINV) are major adverse effects of cancer chemotherapy.
This study investigated: (1) the impact of CINVon patients'
health-related quality of life (HRQL) in daily clinical
practice; (2) the association between patient characteristics
and type of antiemetics and CINV; and (3) the role of CINV
in physicians' decisions to modify antiemetic treatment.
Patients and methods This prospective, multicenter study
was conducted in nine general hospitals in the Netherlands.
During three consecutive chemotherapy cycles, patients
used a diary to record episodes of nausea, vomiting and
antiemetic use. For each cycle, these ratings were made
1 day prior to and 7 days after having received chemother-
apy. The influence of CINV on patients' HRQL was
evaluated with the Functional Living Index-Emesis (FLIE)
questionnaire at day 6 of each treatment cycle. (Changes in)
antiemetic use were recorded by the treating nurse. Patient
inclusion took place between May 2005 and May 2007.
Results Two hundred seventy-seven patients were enrolled
in the study. Acute and delayed nausea during the first
treatment cycle was reported by 39% and 68% of the
patients, respectively. The comparable figures for acute and
delayed vomiting were 12% and 23%. During the first and
subsequent treatment cycle, approximately one-third of the
patients indicated that CINV had a substantial impact on
their daily lives. Female patients and younger patients
reported significantly more CINV than male and older
patients. At all treatment cycles, patients receiving treat-
ment with moderately emetogenic chemotherapy, contain-
ing anthracycline, reported more acute nausea than patients
receiving highly emetogenic chemotherapy. Acute vomiting
was associated significantly with change in (i.e., additional)
antiemetic treatment. Delayed CINV did not influence
antiemetic treatment.
Conclusion CINV continues to be a problem that adversely
affects the daily lives of patients. CINV is worse in women
and in younger patients. In daily clinical practice, acute
CINV, but not delayed CINV, results in changes in
antiemetic treatment. In view of the effects of not only
acute, but also delayed CINV on daily life, more attention
should be paid to adjustment of antiemetic treatment to
cover CINV complaints, later during the chemotherapy
cycle.
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Nausea and vomiting are the most frequently reported
adverse effects of antineoplastic chemotherapy and signif-
icantly affect patients' daily functioning and health-related
quality of life (HRQL) [1]. The development of the 5HT3
antagonists represents a significant advance in preventing
chemotherapy-induced nausea and vomiting (CINV) [2].
More recently, aprepitant, which selectively blocks the
binding of substance P at the NK-1 receptor in the central
nervous system, has been shown to augment the antiemetic
activity of the 5HT3 antagonists and of the corticosteroid
dexamethasone, and thus, to inhibit both acute (i.e., during
or immediately following a chemotherapy cycle) and
delayed (i.e., after chemotherapy) emesis of highly emeto-
genic chemotherapy [3, 4].
Most studies of the effects of CINV on daily life are
characterized by narrow patient selection criteria and are
limited to well-defined chemotherapy and antiemetic
regimens. In addition, most of these studies have been
limited to only a single treatment cycle and were performed
in specialized cancer centers, rather than community
hospitals where the majority of cancer patients are treated.
A recent study, focusing on the effects of chemotherapy
on CINV, and the effect of CINV on daily life found that
36% of all patients reported emesis and 60% reported
nausea. Patients treated with highly emetogenic chemother-
apy (HEC) reported significantly lower mean HRQL
compared to patients treated with moderately emetogenic
chemotherapy (MEC) [5]. However, this study was limited
to 1 cycle of chemotherapy, and the association between
patient characteristics and CINV was not reported.
Retrospective analyses performed on some of the
earliest antiemetic trials, identified a number of patient
and treatment characteristics that appear to have predic-
tive value for the development of CINV [6–9]. Subse-
quent trials evaluating 5HT3 antagonists have, for the
most part, confirmed the predictive value of these factors,
including age, sex, alcohol use, history of motion sickness,
and dose of cisplatin [10–12]. Although many of these
f a c t o r sa r em e n t i o n e di ni n t ernational guidelines on the
treatment of CINV, little is known about their impact on
CINV in daily clinical practice among unselected patients
receiving different types of chemotherapy and antiemetics
[1].
Grunberg et al. found that physicians and nurses could
accurately report the incidence of acute CINV but often (in
75% of the cases) underestimated the incidence of delayed
nausea and emesis after chemotherapy [13]. This would
suggest that delayed CINV is not well managed, as
awareness of the problem is a sine qua non for effective
treatment. In randomized clinical trials on the effectiveness
of antiemetics, the use of the antiemetic schedules is
predefined. Adjustment of antiemetic treatment, based on
the actual level of CINV experienced by the patients, has
not typically been part of the study protocols. So, in fact,
little is known about the adequacy of treatment of CINV
throughout the course of chemotherapy treatment. More
specifically, little is known about the adjustments that are
made in the choice of antiemetics in daily clinical practice
based on patient's self-reported symptoms.
Against this background, we designed our study to: (1)
determine the incidence of CINV during consecutive
treatment cycles in daily clinical practice in general
hospitals; (2) investigate the association between patient
characteristics and types of antiemetics, CINV, and HRQL;
and (3) examine the influence of CINV on changes in
antiemetic therapy, and specifically on adding antiemetics,
over multiple cycles of chemotherapy.
Methods
Study design and setting
This prospective, multicenter, observational study was
conducted in the departments of medical oncology of nine
hospitals in the wider Amsterdam region of the Netherlands
(see Appendix).
Patient sample
The study sample was composed of a consecutive series of
chemotherapy naive patients treated during a 2-year period.
Patients had to be scheduled for treatment with either HEC,
MEC containing anthracycline, or MEC not containing
anthracycline (see paragraph ‘Data collection and study
measures’ for more details). Patients were excluded if they
lacked basic proficiency in the Dutch language, if they were
younger than 18 years of age, or exhibited overt psycho-
pathology or serious cognitive problems that would impede
their ability to take part in the study. Eligible patients were
given both oral and written information about the study
prior to obtaining their informed consent. The institutional
review boards of the participating hospitals approved the
study. Patient inclusion took place between May 2005 and
May 2007.
Data collection and study measures
Patients recorded episodes of nausea, vomiting, and use of
antiemetics in a diary for the day prior to and for 7 days
following each of three consecutive chemotherapy cycles.
Patients were instructed to use the diary everyday to record
each emetic episode and to provide daily nausea assess-
ments using a 100-mm visual analogue scale (VAS) to rate
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24 h. Patients also recorded all rescue antiemetic medica-
tion taken in addition to what was prescribed at baseline to
prevent nausea and vomiting. Only the research team had
access to the patient diaries. Treatment decisions were
based on the physicians' usual patient assessment practice.
Using previously published decision rules, no nausea was
defined as a VAS score of less than 5 mm on the 100-mm
scale. A patient was considered to have had acute nausea or
acute emesis if nausea (VAS>=5 mm), or at least one episode
of vomiting was reported during the first 24 h after start of
chemotherapy [3, 5, 14]. Any episode of nausea and/or
vomiting thereafter up to 5 days after chemotherapy was
considered delayed [5, 14, 15].
In addition, on day 5 after each chemotherapy cycle,
patients were asked to complete the 18-item Functional
Living Index-Emesis (FLIE), a validated self-report ques-
tionnaire designed to evaluate the impact of CINV on
patients' daily lives [16, 17] Response categories range
from one to seven on a modified linear analogue scale. The
total score, calculated by summing the responses to the 18
items, ranges from 18 to 126, with higher scores represent-
ing better health outcomes (i.e., less impact of CINV on
daily life) [18]. Following Bloechl-Daum et al., an
individual item score of six or more, and a total FLIE
score of 108 or more were considered evidence of no or
minimal impact of CINV on daily life [5].
Sociodemographic and clinical information were obtained
via interview, nurse ratings, and/or from the medical records.
This included age, sex, country of origin, WHO performance
status, alcohol intake, prior pregnancy-related emesis, prob-
lems with motion sickness, cancer diagnosis, type of
chemotherapy, radiotherapy, and emetogenicity.
Emetogenicity was defined as HEC (i.e., at least one
chemotherapeutic agent of Hesketh level 5 emetic potential,
such as cisplatin in combination with other chemotherapy),
MEC containing anthracycline (i.e.. at least one anthracy-
cline (doxorubicin, epirubicin) in combination with non-
platinum containing chemotherapy), or MEC not containing
anthracycline (i.e., at least one chemotherapeutic agent of
Hesketh level 3 or 4 emetic potential) [15, 19] Prescribed
antiemetics were recorded by the nurses at each chemo-
therapy cycle.
For interpretation of the use of antiemetics, combinations
of antiemetics were categorized in accordance with inter-
national guidelines. Table 1 summarizes the 2007 NCCN
guidelines on antiemetics. From these guidelines, six
combinations can be defined:
a a combination of a 5HT3 antagonist, a corticosteroid
and aprepitant
b a combination of a 5HT3 antagonist and a
corticosteroid
c a 5 HT3 antagonist
d a corticosteroid
e aprepitant and a corticosteroid
r other antiemetics (for example metoclopramide or a
benzodiazepine)
Statistical analysis
A non-respondent analysis using logistic regression was
performed to compare patient and treatment characteristics
of patients returning all three diaries with those of patients
returning less than three diaries.
Descriptive statistics (means, standard deviations,
percentages) are reported for patient background charac-
teristics and prevalence of CINV. To evaluate the
influence of patient characteristics and type of antiemetic
on CINV, a series of logistic regression analyses was
performed with acute nausea, delayed nausea, acute
vomiting, delayed vomiting, and FLIE scores as depen-
dent variables, and age, gender, emetogenicity, antiemetic
schedule, and alcohol use as independent variables.
Logistic regression analysis was also used to evaluate
the influence of patient and treatment characteristics on
Chemotherapy Antiemetics
Acute CINV (day 1)
High risk 5HT3-antagonist+dexamethasone+aprepitant
Moderate risk 5HT3-antagonist+dexamethasone+aprepitant in selected patients
a
Low risk dexamethasone or metoclopramide or prochlorperazine
Minimal risk No antiemetics
Delayed CINV
High risk Dexamethasone (days 2–4)+aprepitant (days 2–3)+lorazepam in selected
patients
Moderate risk Dexamethasone (days 2–4)+aprepitant if used on day 1 (days 2–3)
a or
5HT3-antagonist (days 2–4)+lorazepam in selected patients
Low en minimal risk No antiemetics
Table 1 NCCN antiemesis
guidelines[1]
aAprepitant should be added to
dexamethasone and a 5-HT3
antagonist for patients receiving
the combination of an anthracy-
cline and cyclophosphamide and
selected patients receiving other
chemotherapies of moderate
emetic risk (e.g., carboplatin,
doxorubicin, epirubicin, ifosfa-
mide, irinotecan, methotrexate)
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variables included age, gender, emetogenicity, CINV, and
alcohol use. Where use of logistic regression was not
possible due to missing cells, the chi-square statistic was
used.
Differences in the prevalence of CINV and the impact
of CINV on daily life over the three chemotherapy cycles
were analyzed using McNemar's test for correlated
proportions [20].
Results
Patients
Two hundred seventy-seven patients were enrolled in the
study. During the course of the study, 52 patients were lost
to follow-up. Five patients died, 4 found the study too
burdensome, 15 did not complete or failed to return the
diary, 6 became too ill to continue participation, 9
discontinued chemotherapy treatment, and 13 patients
discontinued participation for unknown reasons (see
Fig. 1). Data on at least one chemotherapy cycle were
available for 273 patients, two cycles for 253 patients, and
all three chemotherapy cycles for 225 patients.
Table 2 summarizes the sociodemographic and clinical
characteristics of the study sample. The mean age was
56 years (range, 24–87 years). Approximately, one-third of
the patients were male. The most frequent diagnoses were
breast (46.2%), lung (22.7%), and colorectal cancer
(9.7%). Thirty-seven percent of patients received HEC,
51% MEC, containing anthracyclines, and 12% MEC
without anthracyclines.
Results of the non-respondent analysis indicated that in
comparison to those patients returning all three diaries,
those returning less than three diaries were significantly
younger (55 vs 60 years, p=0.02), and were significantly
more likely to have received highly emetogenic than
moderately emetogenic chemotherapy (84% vs 68%, p=
0.02). No significant differences were observed between
full and partial respondents in gender, cancer diagnosis,
WHO performance status, or alcohol use (data not shown in
tabular form).
Incidence of CINV and its effect on daily life (Table 3)
Acute and delayed nausea during the first treatment cycle
were reported by 39% and 68% of the patients, respectively.
The comparable figures for acute and delayed vomiting
were 12% and 23%. Thirty-four percent of the patients
indicated that, overall, CINV during the first treatment
cycle had a significant impact on their daily life (i.e., a total
FLIE score ≤108). The percentage of patients suffering
from CINV and/or reporting CINV, having an impact on
daily life, did not change significantly at the second and
third treatment cycle (Table 3).
Age and CINV (Table 3)
At all treatment cycles, significantly more younger
patients (<65) reported acute chemotherapy-induced
nausea than older patients (first cycle 47% vs 14%, p<
0.005; second cycle 44% vs 21%, p<0.005; third cycle 48
vs 20%, p<0.005). At all treatment cycles, younger
patients experienced more delayed nausea than older
patients; this was statistically significant for the second
treatment cycle (71 vs 46%, p<0.005). A similar pattern
of results was observed for acute vomiting at the second
and third treatment cycles, with significantly more
younger patients reporting vomiting than older patients
(12% vs 3%, p=0.05; and 11% vs 2%, p=0.05). At the
second and the third treatment cycle, significantly more
younger than older patients reported that CINV had an
impact on their daily lives (41% vs 21%, p=0.03 and
44% vs 26%, p=0.05).
Gender and CINV (Table 3)
At the first treatment cycle, female patients suffered
significantly more from CINV than male patients (acute
nausea 48% vs 18%, p<0.005; delayed nausea 75% vs
277 patients enrolled
2 patients 
dropped out
275 patients completed 
1 study course
22 patients 
dropped out
28 patients 
dropped out
253 patients completed 
2 study courses
225 patients completed 
3 study courses
Fig. 1 Patient flow chart. Reasons for patient drop-out during the
study: death (n=5); study too burdensome (n=4); too ill (n=6);
treatment stopped (n=9); failure to return diary/unknown (n=28)
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delayed vomiting 27% vs 14%, p=0.05). A similar pattern
of results was observed at the second and the third
treatment cycles. At the first treatment cycle, significantly
more women than men reported that CINV had a negative
impact on their daily lives (42% versus 22%, p=0.03).
Again, a similar pattern of results was observed at treatment
cycles 2 and 3.
Alcohol use and CINV (Table 3)
The association between alcohol use and CINV was not
entirely consistent. At the first treatment cycle, patients
who consumed more alcohol per week reported signifi-
cantly less acute vomiting than patients consuming less
(p=0.03). This was also found for acute nausea at the third
treatment cycle (p=0.02). However, no other significant
No. of patients Percentage (%)
Sex Female 190 69
Male 85 31
Age, mean (range) 56 (24–87)
Hospital 1 22 7.9
2 7 2.5
3 48 17.3
4 23 8.3
5 19 7.2
6 18 6.5
7 43 15.5
8 46 17.0
9 49 17.7
WHO performance status 0 169 61.4
1 83 30.3
2 14 5.1
3 5 1.8
40 0
unknown 4 1.4
Alcohol use 0 units/week 108 39.4
1–4 units/week 96 34.7
5–10 units/week 34 12.6
11 or more units/week 29 10.5
Unknown 8 2.9
Cancer diagnosis Breast 127 46.2
Lung 62 22.7
Colorectal 27 9.7
Urogenital 7 2.5
Gynecological 11 4.0
Lymphoma 17 6.1
Other 24 8.8
Chemotherapy intent Curative 59 21.7
Adjuvant 115 41.5
Palliative 76 27.8
Neo-adjuvant 18 6.5
Unknown 7 2.5
Emetogenicity of chemotherapy High 101 37
Moderate (anthracycline) 140 51
Moderate (no anthracycline) 34 12
History of pregnancy emesis 43 15.6
History of motion sickness 41 14.9
Table 2 Patient characteristics
(N=275)
a
aThe two patients that dropped
out before completing one study
course were not included in the
analyses
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Acute nausea Delayed nausea Acute vomiting Delayed vomiting FLIE
c
n (%) p-value
a n (%) p-value
a n (%) p-value
b n (%) p-value
a n (%) p-value
a
First course n=275
Gender male 15 (18) 44 (51) 4 (5) 12 (14) 17 (22)
female 92 (48) <0,005 144 (75) 0,009 29 (15) 0,01 51 (27) 0,05 78 (42) 0,03
Emetogenicity HEC 14 (14) 57 (56) 3 (3) 19 (19) 24 (25)
MEC (anthracycline) 82 (59) 105 (75) 27 (19) 37 (26) 58 (43)
MEC (not anthracycline) 11 (31) <0,005 26 (72) n.s. 3 (8) <0,005 7 (19) n.s. 13 (45) 0,02
Age < 65 96 (47) 152 (74) 27 (13) 51 (25) 78 (40)
> 65 10 (14) <0,005 36 (51) n.s. 5 (7) n.s. 12 (17) n.s. 16 (24) n.s.
Alcohol use 0 47 (44) 77 (71) 20 (19) 29 (27) 40 (39)
1–4 units/week 38 (40) 65 (68) 10 (11) 22 (23) 39 (43)
5–10 units/week 11 (31) 20 (57) 3 (9) 6 (17) 6 (18)
11 or more units/week 7 (24) n.s. 18 (62) n.s. 0 (0) 0,03 5 (17) n.s. 8 (30) n.s.
Anti emetic schedule
d A 2 (13) 9 (60) 0 (0) 3 (20) 3 (20)
Day 1 B 74 (40) 127 (68) 23 (12) 42 (22) 65 (37)
C 26 (42) 45 (73) 8 (13) 17 (27) 25 (44)
D 4 (100) 3 (75) 2 (50) 1 (25) 1 (25)
R 1 (13) n.s. 4 (44) n.s. 0 (0) n.s. 0 (0) n.s. 1 (14) n.s.
Anti emetic schedule
d B n.a. 43 (65) n.a. 19 (29) 21 (36)
Day 2 C n.a. 84 (80) n.a. 26 (25) 49 (49)
D n.a. 35 (56) n.a. 10 (16) 17 (28)
E n.a. 11 (61) n.a. 4 (22) 4 (22)
R n.a. 15 (60) n.s. n.a. 4 (16) n.s. 4 (17) n.s.
Anti emetic schedule
d B n.a. 27 (66) n.a. 11 (27) 14 (38)
Day 3 C n.a. 49 (89) n.a. 14 (25) 30 (60)
D n.a. 44 (56) n.a. 17 (22) 22 (29)
E n.a. 10 (56) n.a. 4 (22) 4 (22)
R n.a. 58 (69) 0,03 n.a. 17 (20) n.s. 25 (31) 0,006
Total 107 (39) 188 (68) 33 (12) 63 (23) 95 (34)
Second course n=253
Gender male 10 (13) 35 (47) 2 (3) 9 (12) 15 (21)
female 87 (49) <0,005 130 (73) <0,005 22 (12) 0,02 29 (16) n.s. 75 (43) 0,03
Emetogenicity HEC 10 (11) 41 (47) 3 (3) 11 (13) 15 (17)
MEC (anthracycline) 74 (55) 104 (78) 17 (13) 22 (16) 64 (48)
MEC (not anthracycline) 13 (41) <0,005 20 (63) 0,03 4 (13) n.s. 5 (16) n.s. 11 (37) <0,005
Age < 65 83 (44) 135 (71) 22 (12) 30 (16) 76 (41)
> 65 13 (21) <0,005 29 (46) <0,005 2 (3) 0,05 8 (13) n.s. 13 (21) 0,03
Alcohol use 0 35 (37) 57 (60) 12 (13) 12 (13) 33 (35)
1–4 units/week 43 (46) 67 (71) 10 (11) 17 (18) 41 (45)
5–10 units/week 11 (33) 21 (64) 2 (6) 5 (15) 8 (25)
11 or more units/week 6 (23) n.s. 16 (62) n.s. 0 (0) n.s. 4 (15) n.s. 7 (27) n.s.
Anti emetic schedule
d A 6 (32) 11 (58) 0 (0) 2 (11) 7 (37)
Day 1 B 65 (39) 110 (67) 16 (10) 25 (15) 61 (37)
C 21 (39) 35 (65) 6 (11) 10 (19) 21 (41)
D 3 (50) 5 (83) 2 (33) 1 (17) 0 (0)
R 2 (20) n.s. 4 (40) n.s. 0 (0) <0,005 0 (0) n.s. 1 (10) n.s.
Anti emetic schedule
d B n.a. 43 (75) n.a. 13 (23) 24 (42)
Day 2 C n.a. 65 (71) n.a. 15 (16) 38 (42)
D n.a. 31 (54) n.a. 5 (9) 16 (29)
E n.a. 10 (56) n.a. 2 (11) 7 (39)
R n.a. 16 (52) n.s. n.a. 3 (10) n.s. 5 (18) n.s.
Anti emetic schedule
d B n.a. 28 (78) n.a. 10 (28) 17 (47)
112 Support Care Cancer (2012) 20:107–117Day 3 C n.a. 30 (70) n.a. 6 (14) 21 (50)
D n.a. 40 (56) n.a. 10 (14) 21 (30)
E n.a. 9 (56) n.a. 2 (13) 6 (38)
R n.a. 58 (67) n.s. n.a. 10 (11) n.s. 25 (30) n.s.
Total 97 (38) 165 (65) 24 (9) 38 (15) 90 (35)
Third course n=225
Gender male 10 (16) 25 (40) 1 (2) 13 (21) 15 (25)
female 83 (51) 0,01 127 (78) <0,005 20 (12) 0,02 33 (20) n.s. 69 (45) n.s.
Emetogenicity HEC 7 (10) 35 (48) 1 (1) 15 (21) 14 (21)
MEC (anthracycline) 74 (59) 98 (78) 18 (14) 22 (17) 59 (49)
MEC (not anthracycline) 12 (46) <0,005 19 (73) 0,02 2 (8) 0,01 9 (35) n.s. 11 (48) 0,02
Age < 65 82 (48) 126 (73) 19 (11) 34 (20) 71 (44)
> 65 10 (20) <0,005 25 (48) n.s. 1 (2) 0,05 12 (23) n.s. 12 (26) 0,05
Alcohol use 0 35 (42) 55 (65) 11 (13) 18 (21) 36 (47)
1–4 units/week 44 (51) 64 (74) 8 (9) 18 (21) 27 (45)
5–10 units/week 7 (25) 18 (64) 2 (7) 8 (29) 7 (25)
11 or more units/week 5 (25) 0,02 10 (50) n.s. 0 (0) n.s. 2 (10) n.s. 2 (11) n.s.
Anti emetic schedule
d A 6 (40) 10 (67) 0 (0) 2 (13) 4 (29)
Day 1 B 65 (43) 99 (65) 16 (11) 27 (18) 58 (40)
C 17 (36) 37 (79) 5 (11) 15 (32) 20 (47)
D 2 (50) 3 (75) 0 (0) 1 (25) 0 (0)
R 3 (50) n.s. 3 (43) n.s. 0 (0) n.s. 1 (14) n.s. 2 (40) n.s.
Anti emetic schedule
d B n.a. 40 (69) n.a. 13 (22) 29 (51)
Day 2 C n.a. 53 (80) n.a. 17 (26) 31 (50)
D n.a. 34 (61) n.a. 10 (18) 17 (31)
E n.a. 10 (67) n.a. 1 (7) 3 (23)
R n.a. 15 (50) n.s. n.a. 5 (17) n.s. 4 (16) 0,02
Anti emetic schedule
d B n.a. 23 (68) n.a. 9 (26) 18 (53)
Day 3 C n.a. 32 (86) n.a. 11 (30) 20 (59)
D n.a. 40 (59) n.a. 12 (18) 20 (30)
E n.a. 8 (73) n.a. 0 (0) 2 (20)
R n.a. 29 (65) n.s. n.a. 14 (19) n.s. 24 (36) n.s.
Total 93 (41) 152 (68) 21 (9) 46 (20) 84 (37)
abased on logisitic regression analysis
bbased on chi2 analysis
cthe numbers and percentages present patients with an impact on daily life, a FLIE score of <108 indicaties an impact on daily life
dschedule A is the cmbination of a 5HT3 antagonist, aprepitant and a corticosteroid
schedule B is the combination of a 5HT3 antagonist and a corticosteroid
schedule C is a 5HT3 antagonist
schedule D is a corticosteroid
schedule E is aprepitant and a corticosteroid (day 2 and 3)
schedule R is other anti emetics (for exemple metoclopramide or benzodiazepine)
n.s. not significant
n.a. not applicable
Table 3 (continued)
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CINV.
Emetogenicity of chemotherapy and CINV (Table 3)
At all treatment cycles, significantly more patients receiv-
ing moderately emetogenic chemotherapy, containing
anthracycline, reported acute nausea than patients receiving
highly emetogenic chemotherapy (first cycle 59% vs 14%,
p<0.005; second cycle 55% vs 11%, p<0.005; third cycle
59% vs 10%, p<0.005). In addition, significantly more
patients with moderately emetogenic chemotherapy, con-
taining anthracycline, experienced acute vomiting during
the first and third treatment cycle (19 vs 3%, p<0.005 and
14 vs 1%, p=0.01). At the second and third cycle,
significantly more patients receiving moderately emetogenic
chemotherapy, containing anthracycline, suffered from
delayed nausea (78% vs 47%, p=0.03 and 78 vs 48%, p=
0.02). Also, significantly more patients receiving moderately
emetogenic chemotherapy, containing anthracycline, reported
that CINV had a negative impact on daily life at all treatment
cycles(firstcycle43%vs25%,p=0.02; second cycle 48% vs
17%, p<0.005; third cycle 49 vs 21%, p=0.02).
Antiemetic use and CINV (Table 3)
As described in the methods section, the different combi-
nations of antiemetics were classified in six different groups
paralleling the combinations of antiemetics described in the
international guidelines summarized in Table 1 [1].
HEC In our study, 15% of patients receiving HEC were
treated with antiemetics containing aprepitant, a 5HT3
antagonist and dexamethason; 55% of the HEC patients
were treated with a combination of a 5HT3 antagonist and
dexamethason, and 25% with a 5HT3 antagonist as a single
agent. On day 2, 30% of the HEC patients were treated with
a combination of a 5HT3 antagonist and a corticosteroid,
24% with a 5HT3 antagonist alone, and 16% with a
corticosteroid alone. On day 3, these combinations of
antiemetics were used in 24%, 16%, and 22% of cases,
respectively. Patients treated with a combination of antie-
metics containing aprepitant on day 1, were also treated
with aprepitant on days 2 and 3. The remaining patients
were treated with other types of antiemetics, e.g., metoclo-
pramide, benzodiazepines.
MEC No MEC-A patients were treated with aprepitant;
80% of these patients were treated with a combination of a
5HT3 antagonist and dexamethason for acute CINV.
On day 2, 20% of the MEC-A patients were treated with
the combination of a 5HT3 antagonist and dexamethason,
46% were treated with a 5HT3 antagonist as single agent,
and 29% with dexamethason as single agent. On the third
day after chemotherapy, the percentages on these treatment
combinations were 10%, 21% and 34%, respectively. The
remaining patients were treated with other types of
antiemetics, e.g., metoclopramide, benzodiazepines.
In general, very few statistically significant associations
were observed between type of antiemetic used and CINV.
Eighty-nine percent of patients using a 5HT3 antagonist at
the third day after the first cycle of chemotherapy suffered
from delayed nausea, compared to 56% of patients using a
combination of aprepitant and a corticosteroid or a
corticosteroid as a single agent (p=0.03). This was also
reflected in the percentage of patients in these two
subgroups reporting CINV-related effects on their daily
lives (60% vs 22%, p=0.006). At the second treatment
cycle, no patient using a combination of antiemetics
(aprepitant, 5HT3 antagonist, and a corticosteroid) suffered
from acute vomiting, compared to 33% of patients using a
corticosteroid (p<0.005).
Adding antiemetics between treatment cycles (Table 4)
To evaluate changes in (i.e., the addition of) antiemetics
between treatment cycles and the factors affecting those
changes, we compared the (combination of) antiemetics
used on day 1 of the first cycle with those used on day 1 of
cycles 2 and 3. The same comparison was done for the
antiemetics used on days 2 and 3 of the first cycle with
those used on days 2 and 3 of cycles 2 and 3.
Table 4 shows the results of the logistic regression
analysis based on patients for whom additional antiemetics
were added over the course of their treatment. On the first
day of the treatment cycle (the day the chemotherapy was
administered), patients suffering from acute vomiting were
significantly more likely to receive extra antiemetics than
patients not suffering from these symptoms (acute vomiting
34 vs 14%, p=0.009). However, the experience of CINVon
the second and third day after the administration of
chemotherapy did not result in the use of additional
antiemetics.
On day 1, 42 patients received additional antiemetics;
64% of these patients received extra corticosteroids and
17% aprepitant. On day 2, 43 patients received additional
antiemetics, of whom 56% were treated with extra cortico-
steroids and 21% with 5HT3 antagonist. On day 3, 54
patients received additional antiemetics, of whom 35%
were treated with a 5HT3 antagonist, and 35% with a
corticosteroid. The remaining patients were treated with
other extra types of antiemetics, e.g., metoclopramide,
benzodiazepines. Logistic regression analysis did not show
improved symptom control due to the addition of these
antiemetics.
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Chemotherapy-induced nausea and vomiting have a clear
impact on the daily lives of cancer patients. Antiemetic
therapy is aimed at preventing, ameliorating or minimizing
CINV. Most studies of the effects of CINV have been
characterized by narrow patient selection criteria and have
investigated well-defined, protocol-based chemotherapy,
and antiemetic regimens.
The results of this study of CINV and antiemetic use in
routine clinical practice indicate that CINV and particularly
delayed symptoms, impact significantly on patients' daily
life, despite the use of different combinations of antiemet-
ics. Our findings are consistent with those of other studies,
in which the prevalence of delayed nausea and vomiting is
higher than acute nausea and vomiting [5].
However, contrary to expectations, we found that
patients receiving treatment with moderately emeto-
genic chemotherapy containing anthracyclines (MEC-
A) suffered more from CINV than patients receiving
HEC.
A previous study in daily clinical practice by Bloechl-
Daum reported no significant differences in the rate of
acute and delayed nausea between patients treated with
HEC and MEC, while significantly more patients
receiving HEC than MEC reported that CINV had a
negative impact on daily life (52.8% and 35.5%, p=
0.027) [5]. However, Mollassiotis et al. reported that
patients receiving MEC experienced higher levels of
CINV compared to patients receiving HEC in a large,
single center study in the UK [21]. These two studies were
conducted before antiemetic guidelines incorporated the
use of NK-1 receptor antagonist containing regimens for
patients receiving HEC. After completion of our study,
antiemetic guidelines for MEC-A were also updated.
Currently, a three-drug combination regimen, including
Table 4 Association between CINV symptoms and use of additional antiemetic medications during subsequent chemotherapy cycles (n=225)
Day 1 Day 2 Day 3
n (%) OR p value n (%) OR p value n (%) OR p value
Age <65 years 31 (16) 33 (17) 40 (21)
>65 years 11 (17) 1 0.97 8 (13) 1 0.27 13 (21) 1 0.81
Sex Male 10 (13) 9 (12) 11 (15)
Female 32 (18) 0.7 0.41 33 (18) 0.7 0.54 42 (23) 0.6 0.28
Emetogenicity HEC 16 (18) 12 (14) 13 (15)
MEC with
anthracycline
24 (18) 28 (21) 36 (27)
MEC without
antracycline
2 (6) 0.57 0.11 2 (6) 0.7 0.3 4 (13) 1 0.95
Alcohol use 0 units/week 15 (16) 0.4 15 (16) 0.7 18 (19) 0.8
1–4 units/week 13 (14) 0.5 17 (18) 0.8 24 (26) 1.2
5–10 units/week 6 (18) 0.6 3 (9) 0.4 5 (15) 0.6
11 or more
units/week
6 (23) 0.52 5 (19) 0.67 5 (19) 0.53
Acute vomiting
1st course
Yes 10 (34) 8 (28) 8 (28)
No 32 (14) 5.7 0.009 34 (15) 0.5 0.29 45 (20) 0.4 0.17
Acute vomiting
2nd course
Yes 4 (17) 5 (21) 5 (21)
No 38 (17) 0.4 0.56 37 (16) 1.5 0.56 48 (21) 2.1 0.29
Delayed vomiting
1st course
Yes 28 (14) 31 (16) 43 (22)
No 14 (24) 1.5 0.4 11 (19) 0.8 0.57 10 (17) 0.43 0.06
Delayed vomiting
2nd course
Yes 35 (16) 32 (15) 41 (19)
No 7 (18) 1 0.96 10 (26) 2.2 0.12 12 (32) 2.3 0.07
Acute nausea
1st course
Yes 23 (15) 22 (14) 29 (18)
No 19 (20) 0.8 0.73 20 (21) 0.6 0.34 24 (25) 1.1 0.88
Acute nausea
2nd course
Yes 26 (17) 19 (12) 31 (20)
No 16 (16) 2.3 0.11 23 (23) 2.4 0.09 22 (23) 0.7 0.39
Delayed nausea
1st course
Yes 7 (8) 10 (12) 12 (14)
No 35 (20) 2.6 0.07 32 (19) 1.3 0.59 41 (24) 1.7 0.24
Delayed nausea
2nd course
Yes 12 (13) 11 (12) 14 (16)
No 30 (18) 1.1 0.83 31 (19) 0.8 0.63 39 (24) 1.2 0.76
Support Care Cancer (2012) 20:107–117 115an NK-1 receptor antagonist, is also recommended for
MEC-A regimens [1]. Our finding that patients who
received MEC treatment faired particularly poorly in
terms of CINV symptoms may be explained, at least in
part, by the fact that these patients did not receive newer
and more effective antiemetic treatment including aprepi-
tant. Additional studies are needed to determine the
effectiveness in daily clinical practice of newer antiemetic
treatments among patients receiving MEC-A.
Various other factors, in addition to the emetogenicity
of the chemotherapy, have been identified that influence
both the prevalence and the severity of CINV. These
include age, gender, alcohol use, history of motion
sickness, and history of pregnancy-related vomiting. In
our study, the first three of these risk factors were found
to be associated significantly with CINV, but not the
latter two. It is unclear why this is the case. It may be
that once female gender, which was a strong predictor
variable, entered the logistic regression model, motion
sickness and pregnancy-related vomiting did not have
any additional predictive value.
Interestingly, in a recent analysis of data from two phase
III trials of aprepitant in patients receiving cisplatin-based
chemotherapy, female gender was not found to be a
significant risk factor for CINV [22]. It would be of interest
to determine if this also holds true for patients receiving
MEC-A, because the majority of these patients are women
being treated for breast cancer with anthracycline-
containing regimens.
Given the finding that patients lost to follow-up were
younger and significantly more likely to receive HEC,
patients' level of CINV after multiple treatment cycles
might be underestimated in our study because of the
increased risk of CINV associated with these risk factors.
The current study is, to the best of our knowledge, the
first to investigate change in antiemetic use, and specifi-
cally, the use of additional antiemetics, during consecutive
cycles of chemotherapy. Previous studies on CINV over
multiple treatment cycles have been carried out in well-
defined patient populations using predefined antiemetic
regimens that were held constant throughout the chemo-
therapy treatment [23]. In our study, we found that patients
experiencing acute vomiting were significantly more likely
to have antiemetics added in subsequent chemotherapy
cycles than those not experiencing acute vomiting. How-
ever, no significant association was observed between other
symptoms of CINV and the use of additional antiemetics
during subsequent treatment cycles. Additionally, our
results indicate that delayed CINV had no effect on
subsequent antiemetic treatment. This may be due, in part,
to the fact that physicians and nurses often underestimate
the incidence of delayed nausea and vomiting [13]. The
introduction of standardized, clinic- and home-based
symptom monitoring (the latter via interactive voice
recognition systems or internet-based data capture) could
provide health care providers with real time information on
delayed CINV, which, in turn, could have a salutary effect
on symptom management.
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Appendix
Contributing hospitals, hospital pharmacists, and oncology
nurses: Diaconessenhuis Leiden: G. Wassink, D. van Hooff,
E. Kulk; Gemini Ziekenhuis: G. Nap, R. Timmerman, E.
Beer; Medisch Centrum Alkmaar: P. Kloeg, S. de Bie,
M. Jong; Onze Lieve Vrouwe Gasthuis: C. van der
L i n d e n ,M .A t t e m a - d ej o n g e ,J . M .J e n j e ,P . W .v a nd e r
V e l d e ,N . W . M .G e r r i t s ,E . B .G o o s z e n ,B .d eV a l k ;
Rijnland ziekenhuis:J.M.R. Hollander, I. Borst, E. van
Belsen; Sint Lucas Andreas ziekenhuis: J. van den Heuvel,
P. den Hartogh, J. van de Klooster, G. Kuper, K. Keijzer,
E. vd Boogaard; Waterland ziekenhuis; R. de Jong, C. Boers;
WestFries Gasthuis: B. van der Kleij, M. Plas, B. Vonk,
M. Dudink; Zaans Medisch Centrum: M.G. Schuitenmaker,
C. Bakker, M. Termeulen, M. de Waard
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